# Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)

> **NCT04808999** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Diwakar Davar** · enrollment: 30 (actual)

## Conditions studied

- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab Injection

## Key facts

- **NCT ID:** NCT04808999
- **Lead sponsor:** Diwakar Davar
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-11
- **Primary completion:** 2024-04-12
- **Final completion:** 2029-04-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-05-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04808999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04808999, "Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04808999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*